Theravance Biopharma, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value
Theravance Biopharma, Inc. (TBPH) had Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value of $0 as of 2015-09-30, per its 10-Q filed 2015-11-12.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue · last filed 2015-11-12
- 2015-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value |
|---|---|
| 2015-09-30 | $0.00 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |